首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到18条相似文献,搜索用时 171 毫秒
1.
目的 探索血清白细胞介素-33(IL-33)与绝经后骨质疏松女性骨密度和骨代谢指标相关性。方法 采用酶联免疫吸附法测定50例绝经后骨质疏松患者和50例正常绝经后妇女血清IL-33水平。采用双能X线骨密度仪(DXA)测量患者和对照组的骨密度(BMD)。检测维生素D、钙、碱性磷酸酶(ALP)、甲状旁腺激素(PTH)水平,以及1型胶原C末端肽(CTX)和1型前胶原N端前肽(P1NP)等骨转换指标。结果 在绝经后骨质疏松症女性中,IL-33水平显著低于健康对照组[(3.53±2.45) pg/mL vs (13.72±5.39) pg/mL,P=0.007];Spearman相关分析表明血清IL-33水平与年龄、BMI、PTH、CTX和P1NP水平呈负相关,与腰椎BMD和股骨颈BMD呈正相关。多元回归分析表明,年龄、BMI、腰椎BMD、PTH、股骨颈BMD和血清CTX和P1NP水平是骨质疏松症患者血清IL-33水平降低的独立预测因子。结论 血清IL-33降低是绝经后骨质疏松患者股骨颈和腰椎骨密度降低和骨转换增速的危险因素。  相似文献   

2.
目的对西安地区部分骨质疏松症患者血清骨代谢标志物进行统计及相关性分析。方法纳入2018年4月至2019年3月经西安市红会医院诊治的原发性骨质疏松症患者295例,检测受试者血清钙(Ca)、磷(P)、碱性磷酸酶(ALP)、维生素D(vitamin D,维生素D)、甲状旁腺素(PTH)、I型前胶原N端肽(P1NP)、β-胶原特殊序列(β-Cross)的水平,运用R统计语言进行统计学处理及Pearson相关性分析。结果在大多数骨质疏松症患者中血清Ca、P是正常的;有20%~30%患者ALP升高;绝大多数患者维生素D缺乏或不足;PTH异常者以升高为主,少数女性患者PTH降低;大多数绝经前女性P1NP、β-Cross正常,在少数绝经前女性及1/3男性中出现升高,小部分绝经后女性出现下降,在小部分绝经后女性中升高。女性骨质疏松症患者中,血清ALP与P1NP、ALP与PTH、维生素D与β-Cross呈正相关(P<0.05),血清Ca与β-Cross、P与ALP、P与β-Cross、P与PTH、ALP与维生素D、ALP与β-Cross、维生素D与P1NP、维生素D与PTH、P1NP与β-Cross呈负相关(P<0.05)。男性骨质疏松症患者中,血清维生素D与β-Cross呈正相关(P<0.05),血清Ca与PTH、ALP与维生素D、维生素D与P1NP、维生素D与PTH、P1NP与β-Cross呈负相关(P<0.05)。结论骨质疏松症患者维生素D缺乏或不足情况严重,了解骨代谢标志物间的相关性有助于更好地理解骨质疏松症骨代谢异常机制。  相似文献   

3.
目的 探讨绝经后妇女血清骨硬化蛋白水平与体脂含量及骨密度(bone mineral density, BMD)之间的相关性。方法 对230名年龄在50~75岁之间健康的绝经后妇女进行横断面研究。通过双能X射线吸收仪测量受试者全身、腰椎、左侧股骨BMD及全身脂肪和肌肉含量。通过定量夹心酶联免疫吸附法测量受试者血清骨硬化蛋白水平。结果 与非骨质疏松症的女性相比,骨质疏松女性血清硬化蛋白水平显著降低(P <0.05)。血清骨硬化蛋白水平与体重和脂肪量呈正相关(P <0.05)。即使在校正年龄、绝经年龄、身高和体重之后,骨硬化蛋白水平与全身及各个部位的BMD均呈正相关(P <0.05)。多元线性逐步回归分析显示,与年龄、绝经年龄、脂肪量和肌肉量相比,血清骨硬化蛋白水平是全身和腰椎BMD最重要的决定因素(P <0.05)。年龄与血清硬化蛋白对髋部BMD的影响相似。结论 在绝经后妇女中,骨质疏松症患者的血清硬化蛋白水平低于非骨质疏松症患者。血清硬化蛋白与全身、腰椎、髋部的BMD和体脂含量呈正相关。  相似文献   

4.
目的探讨骨代谢标志物对预测绝经后骨质疏松患者合并腰椎骨折风险的诊断价值。方法采用双能X线骨密度仪、酶联免疫检测法(ELISA)和速率法对70例绝经后骨质疏松症腰椎无骨折患者和70例绝经后骨质疏松症腰椎骨折患者的髋部及腰椎骨密度、各项骨代谢生化指标进行检测,并分析骨代谢生化指标的变化与骨质疏松症、骨质疏松性腰椎骨折之间的相关性。结果绝经后骨质疏松性腰椎骨折的发生风险与年龄、体重、身高、体重指数、骨密度等一般指标和骨钙素N端中分子片段(N-MID osteocalcin,N-MID)、骨碱性磷酸酶(bone alkaline phospha,BAP)、钙离子(calcium ionic,Ca~(2+))、骨吸收标志物β-Ⅰ型胶原羧基端肽(β-C-terminal telopeptide of type I collagen,β-CTx)等生化指标之间无关联,而与血清I型原胶原氨基端延长肽(propeptide of type I procollagen,PINP)、抗酒石酸酸性磷酸酶5b(TRAP-5b)和25-羟维生素D(25-hydroxy vitamin,25-(OH)D)之间存在显著相关性(P=0.002、0.007、0.001),其中与PINP、TRAP-5b呈正相关,与25-(OH)D呈负相关。结论绝经后女性血清PINP、TRAP-5b和25-(OH)D与骨质疏松性骨折的发生存在显著的相关性,骨代谢标志物与骨密度的联合检测对预测绝经后骨质疏松腰椎骨折具有一定的临床意义。  相似文献   

5.
目的了解雌二醇和白细胞介素-6等骨代谢指标在骨质疏松症发病中的作用。方法选择女性腰椎骨折患者120例,绝经后有骨质疏松者60例(OP组),绝经后无骨质疏松者30例(NOP组),另外选择绝经前妇女30例为对照组。对120名妇女雌二醇、骨密度、白细胞介素-6、血清总碱性磷酸酶、骨钙素、尿羟脯氨酸肌酐比值、尿钙肌酐比值等指标进行了测定。结果绝经后妇女骨形成指标骨钙素及碱性磷酸酶明显高于对照组妇女,其中碱性磷酸酶在OP组和NOP组间有差异,而骨钙素在OP组和NOP组间无差异;绝经后妇女骨吸收指标尿羟脯氨酸肌酐比值及尿钙肌酐比值明显高于对照组妇女,OP组又明显高于NOP组;绝经后妇女的血清雌二醇的含量明显低于对照组(绝经前妇女),OP组又明显低于NOP组;绝经后妇女血清白细胞介素-6的含量明显高于对照组妇女,而OP组又明显高于NOP组。结论雌二醇、白细胞介素-6等骨代谢指标与骨质疏松关系密切。这充分说明雌激素水平的下降,IL-6分泌增多,导致骨吸收加速。  相似文献   

6.
绝经前子宫切除妇女骨代谢变化与卵巢功能的相关性研究   总被引:2,自引:0,他引:2  
目的 探讨绝经前子宫切除妇女骨代谢变化与卵巢功能的相关性.方法 随机抽取绝经前行单纯子宫切除术患者印例,按手术后时间分为1年组、2年组、≥3年组,另随机抽取子宫附件正常妇女20例做对照组.采用化学发光法及酶联免疫吸附法(ELISA法)检测雌二醇(E2)、促卵泡素(FSH)、孕激素(P)及血碱性磷酸酶(ALP)、骨钙素(BGP)、尿脱氧吡啶(DPD),做两组功能指标的相关性分析.结果 手术后≥3年组ALP、BGP、DPD水平与E2呈负相关,DPD、BGP与FSH呈正相关,ALP与FSH相关性不显著.术后2年组DPD水平与E2呈负相关,BGP、ALP与E2,BGP、ALP、DPD与FSH相关性不显著.对照组、术后1年组上述指标无相关性.结论 随着手术闭经时间的延长ALP、BGP、DPD水平与E2、.PSH的相关性显著,表明绝经前子宫切除妇女体内骨代谢变化与卵巢功能有密切关系.  相似文献   

7.
目的比较住院维汉2型糖尿病女性骨代谢指标,并研究相关影响因素。方法纳人住院的2型糖尿病维汉女性患者 共264人,维吾尔族172人,汉族92人,空腹抽血查碱性磷酸酶(ALP),骨钙素(BGP),血钙(Ca)、维生素D3 ( VitD3),雌二醇 (E2),血清总睾酮(T),糖化血蛋白(HbA1C),测量身高、体重,腹围,并计算BMI。结果维汉两组年龄,病程,绝经情况,E2 及T无统计学差异,P >0.05,而腹围,BMI,HbA1 c,ALP及BGP水平较汉族组高,尸<0. 05,血钙及VitD3水平略低于汉族组,P <0.05。多元线性回归分析中,BGP存在民族差异(P =0.002),绝经患者的骨钙素水平高于未绝经者(P = 0.003);BMI与骨 钙素的水平呈负相关(P =0. 001)。结论维吾尔族2型糖尿病女性患者的BGP水平较汉族患者略高,无论种族如何,BGP的 水平与BMI呈负相关,绝经后女性的BGP水平显著高于绝经前女性。  相似文献   

8.
绝经后妇女血清调钙激素水平与骨代谢关系探讨   总被引:9,自引:1,他引:8       下载免费PDF全文
目的 探讨绝经后妇女血清调钙激素水平对骨形成、骨吸收及骨密度的影响。方法 142名健康绝经后妇女测定血雌二醇(E2)、睾酮(T)、总三碘甲状腺原氨酸(TT3)、总甲状腺素(TT4)、甲状旁腺激素全段(PTH-SP)、降钙素(CT)、骨钙素(BGP)、尿脱氧吡啶啉(DPD)、尿肌酐(Cr)。双能X线骨密度仪测定腰椎、髋部、前臂骨密度(BMD),对检测结果进行分析。结果 本组骨质疏松患病率为60.48%,低骨量32.39%,正常骨量7.13%。血清6种调钙激素中T、E2、TT3、TT4、CT与BMD、BGP呈正相关,与年龄负相关;PTH-SP与BMD呈负相关,与年龄、DPD/Cr呈正相关。结论 绝经后妇女血调钙激素水平影响骨形成、骨吸收和骨密度,使骨代谢趋向于负平衡,是绝经后妇女易发生骨质疏松症的重要原因。  相似文献   

9.
卜淑敏  张立萌 《中国骨质疏松杂志》2021,(7):1000-1004, 1041
目的分析高校大学生循环骨钙素水平及其与选择的钙调节激素、骨及糖脂代谢指标之间的相关性。方法通过问卷调查和血液指标检测,从某大学筛选出103名符合试验要求的非体育专业在校大学生。将受试者按照性别分为男性组和女性组,采用简单和多重线性回归分析两组受试者血清骨钙素水平的相关因素。结果男大学生血清骨钙素水平显著高于女大学生。Pearson相关分析结果表明,男大学生血清骨钙素水平与年龄和体质量指数(body mass index,BMI)呈负相关,而与血清甲状旁腺激素(parathyroid hormone,PTH)和碱性磷酸酶(alkaline phosphatase,ALP)水平呈正相关。经身体形态学指标校正后,与胰岛素水平和稳态模型评估胰岛素抵抗指数呈正相关;女大学生血清骨钙素水平与体重和BMI呈负相关,而与血清PTH、ALP、磷和空腹血糖(fasting blood glucose,FBG)水平呈正相关。经身体形态学指标校正后,与血清25羟维生素D [25-hydroxyvitamine D,25(OH) D]、钙、高密度脂蛋白胆固醇和FBG水平呈正相关。多重线性回归分析进一步表明,男大学生血清骨钙素水平与年龄和BMI独立负相关,而与血清PTH水平独立正相关;女大学生血清骨钙素水平与FBG水平独立正相关。结论高校大学生循环骨钙素水平及其与年龄、BMI、PTH和FBG水平的独立相关性具有性别差异。  相似文献   

10.
目的探讨血清总胆红素在绝经后骨质疏松症发病机制中的作用。方法通过双能X线骨密度仪检查,将282例绝经后女性分为正常骨量组(n=93)和早期绝经后骨质疏松症组(n=61)、中期绝经后骨质疏松症组(n=58)和晚期绝经后骨质疏松症组(n=70)。测定血清总胆红素和骨转换标志物水平,分析血清总胆红素与骨密度、骨代谢的关系。结果骨密度与年龄、I型胶原交联C-末端顶端肽(β-CTX)、甲状旁腺激素(parathyroid hormone,PTH)呈负相关,与体重指数(body mass index,BMI)、25羟基维生素D3(25(OH_2)D_3)、血清总胆红素(total bilirubin,TBIL)呈正相关。Logistics回归分析显示,年龄、BMI、TBIL、PTH、总I型前胶原N-末端肽与骨质疏松症的发生独立相关,而血清碱性磷酸酶(alkaline phosphatase,ALP)、β-CTX与绝经后骨质疏松无独立相关性。结论血清总胆红素水平下降为绝经后骨质疏松症的独立危险因素。  相似文献   

11.
目的 观察铁过载对绝经后骨质疏松患者骨密度和骨代谢的影响。方法 将234名绝经后妇女按照骨密度(bone mineral density, BMD)分为正常组、骨量减少组和骨质疏松组。分析铁过载对年龄、绝经年数、血钙(Ca)、磷(P)、体质量指数(bone mass index,BMI)、肝肾功能、葡萄糖代谢、脂质代谢、炎症反应、BMD、抗酒石酸酸性磷酸酶5b(TRACP-5b)、ALP、Ⅰ型胶原交联C端肽(β-CTX)和Ⅰ型胶原交联N端肽(PINP)的影响。结果 与正常组相比,骨量减少组和骨质疏松组血清铁蛋白(Fer)显著升高(P<0.05)。Fer水平与BMD呈负相关(P<0.05)。TRACP-5b水平在骨质疏松组明显高于正常组(P<0.05)。与正常组相比,骨质疏松症组的ALP水平显著升高(P<0.05)。与骨量减少组相比,骨质疏松组血清β-CTX水平明显升高(P<0.05);且骨质疏松组的PINP水平显著高于正常组(P<0.05)。更重要的是,血清Fer和PINP之间存在正相关(P<0.05);血清Fer和β-CTX之间呈正相关(P<0.05)。结论 铁过载对绝经后骨质疏松患者骨密度和骨代谢均有显著影响。  相似文献   

12.
A total of 26 subjects, 13 premenopausal and 13 postmenopausal women, aged between 46 and 52 were examined for their cortical thickness of the clavicle, serum bone gamma-carboxyglutamic acid-containing protein (BGP, osteocalcin), serum alkaline phosphatase, serum calcium, serum inorganic phosphate, urinary calcium/creatinine and urinary inorganic phosphate/creatinine. Serum BGP was significantly higher in postmenopausal than in premenopausal women. Serum alkaline phosphatase also tended to elevate in postmenopausal women, while there were no significant differences in cortical thickness of the clavicle, serum calcium, serum inorganic phosphate, urinary calcium/creatinine and urinary inorganic phosphate/creatinine between the two. Considering that both serum BGP and serum alkaline phosphatase are markers of bone formation, these findings indicate that menopause firstly accelerates bone turnover preceding age-related bone loss.  相似文献   

13.
Bone density change and biochemical indices of skeletal turnover   总被引:9,自引:0,他引:9  
Although biochemical markers of skeletal turnover cannot replace bone density scanning for the diagnosis of osteoporosis, it is thought that they may help add to prediction of fracture risk and help determine adequacy of osteoporosis therapy. Nevertheless, whether biochemical markers in the serum or urine can predict individual rates of bone loss in the spine or hip region is unknown. We studied a heterogeneous group of women (n=81) who were premenopausal, untreated postmenopausal, and estrogentreated postmenopausal with baseline determination of body mass index (BMI), calcium intake, biochemical measurements, and serial bone densitometry over 3 years. Serum assays included bone Gla protein (BGP), total and bonespecific specific included bone Gla protein (BGP), total and bone-specific alkaline phosphatase (AP, BSAP), carboxyterminal propeptide of type I procollagen (PICP), carboxyterminal telopeptide of type I collagen (ICTP) and tartrate-resistant acid phosphatase (TRAP). Urine assays included hydroxyproline (OHP), calcium, total pyridinoline, and total deoxypyridinoline. Individual biochemical markers and calcium intake were modestly correlated with bone density changes but were inconsistent regarding the spine versus the hip. All of the formation variables were significantly correlated to spine density change (r=−0.24 to −0.49) whereas the only resorption variable that correlated was urine OHp/Cr (r=−0.31). The only formation variable that correlated with hip density change was serum PICP whereas all of the resorption variables except serum TRAP were correlated (r=−0.23 to −0.35). “High turnover” individuals were defined as those with levels of biochemical variables at least 1 SD above the mean young normal for each variable. Higher bone loss rates were seen in this group for several of the turnover markers compared with bone loss rates in all other individuals. However, the sensitivity of this “high turnover” status for identifying high bone losers did not exceed 60% for any of the variables. In untreated postmenopausal women, a model using urine OHp, serum ICTP, serum BSAP, and calcium intake was able to predict 42% of the variance of change in BMD of the lumbar spine. A model using BMI, serum ICTP, and serum BGP could predict 32% of the variance of change in BMD of the femoral neck. No combination of markers could predict variance in bone density change at either site in estrogenized women (premenopausal and estrogen-treated postmenopausal). We conclude that measuring individual serum and urine markers of bone turnover cannot accurately predict bone loss rates in the spine and hip; however, combinations of demographic and biochemical variables could predict some of the variance in untreated postmenopausal women. Biochemical markers cannot replace serial bone densitometry for accurate determination of change in bone mass at the most clinically relevant sites.  相似文献   

14.
Urinary excretion of cross-linked N-telopeptide of type I collagen (NTx) has been reported to be a specific marker of bone resorption [18]. We assessed a new immunoassay for NTx as an indicator of changes in bone resorption caused by spontaneous menopause and compared cross-sectionally the levels of urinary NTx, hydroxylysylpyridinoline (HP), lysylpyridinoline (LP), hydroxyproline (OH-Pr), other serum biochemical indices, and lumbar spine and proximal femur bone mineral density (BMD). Eighty-one Japanese women aged 22–77 participated in this study; 36 were premenopausal and 45 were postmenopausal. Urinary HP, LP, and NTx stayed at low levels in the premenopausal period and rose 21%, 30%, and 67% in the postmenopausal period, respectively. The rise in LP and NTx was statistically significant (P < 0.01), suggesting that NTx is mostly released from bone matrix when bone resorption is accelerated. When premenopausal women were divided into two age groups and postmenopausal women were divided into two groups according to years since menopause (YSM) there were significant differences in LP and NTx between women <4 YSM and women aged <40 and those women aged 41+ (P < 0.01 and P < 0.05, respectively). A significant 110% increase in urinary NTx and a 48% increase in urinary LP were observed in postmenopausal women compared with age-matched premenopausal women aged 45–55. All biochemical markers other than serum PTH correlated significantly with each other (r = 0.243–0.858, P < 0.05–0.0001). Urinary NTx inversely correlated with lumbar spine BMD. When postmenopausal women were divided into three groups, the correlation between bone resorption and formation markers in women 0-1 YSM was greater than in women 2–10 YSM and in women 11 + YSM, indicating that resorption and formation are coupled at the early postmenopausal period. We conclude that urinary NTx is responsive to changes in bone metabolism caused by estrogen deficiency and may be a more sensitive and specific marker than HP, LP, or OH-Pr in the early postmenopausal years. Received: 15 February 1995 / Accepted: 18 October 1996  相似文献   

15.
Urinary pyridinoline (pyr) and deoxypyridinoline (dpyr) are new markers for bone resorption, and serum osteocalcin reportedly indicates osteoblastic activity. Recently, a new ultrasound bone densitometer instrument has been developed that measures ultrasonic properties of the os calcis, namely, the speed of sound (SOS), broadband ultrasound attenuation (BUA), and stiffness index. The effects of menopause on biochemical markers and ultrasound densitometry were investigated in 40 healthy females, 36–39 years, with regular menstruation, and in 117 healthy perimenopausal females, 47–57 years, who were divided into a premenopausal group and a postmenopausal group. Significantly elevated values of pyr, dpyr, and serum osteocalcin were found for the postmenopausal group as a whole compared with the premenopausal group. We examined postmenopausal groups 48–57 years of age stratified into 2-year intervals (within 2 years of the menopause, 2–4 years postmenopause and 4–6 years postmenopause). Elevated values of urinary pyr, dpyr, and serum osteocalcin were evident even in the first 2 years postmenopause compared with the premenopausal group, and these higher values were exhibited until 6 years after menopause. We found a significant decrease in SOS, BUA, and stiffness index of the postmenopausal group as a whole, compared with those of the premenopausal group. SOS, BUA, and stiffness index of the group within 2 years of menopause significantly decreased compared with those of the premenopausal group. The Z-scores of the increase in biochemical markers and the decrease in stiffness index in the postmenopausal group were approximately 0.7–1.3 compared with the premenopausal group. The results suggest that these biochemical markers and ultrasound densitometry are potentially sensitive parameters of postmenopausal bone change.  相似文献   

16.
 The aim of this study was to clarify the relationship between endogenous estrogen, sex hormone-binding globulin (SHBG), and bone loss in pre-, peri-, and postmenopausal female residents of Taiji, a rural Japanese community. From a list of inhabitants aged 40 to 79 years, 200 participants—50 women in each of four age decades—were randomly selected, and baseline bone mineral density (BMD) at the lumbar spine and proximal femur were measured by dual-energy X-ray absorptiometry in 1993. Total estradiol (total E2) and SHBG were measured, and SHBG-unbound E2 (UBE2) was calculated using SHBG and the percent SHBG-unbound fraction ratio. BMD was measured again 3 years later, in 1996. Participants with ovariectomy or hysterectomy were excluded, and the remaining participants were categorized into four groups: premenopausal (n= 38), perimenopausal (n= 14), postmenopausal group 1 (5 years or less since menopause; n= 18), and postmenopausal group 2 (6 years or more since menopause; n= 74). The mean value of total E2 was highest in the premenopausal group (49.1 pg/ml), followed by the perimenopausal group (26.4 pg/ml), and the postmenopausal groups (0.83 pg/ml in postmenopausal group 1 and 0.96 pg/ml in postmenopausal group 2). The means for UBE2 showed the same pattern across the groups. After the multiple regression analysis of BMD at follow-up and endogenous estrogens, in premenopausal women, there were no significant associations between BMD at follow-up and serum total E2 and UBE2. In perimenopausal women, however, serum total E2 and UBE2 were significantly correlated with trochanteric BMD at follow-up (P < 0.05); and in postmenopausal group 2, they were significantly correlated with lumbar spine and Ward's triangle BMD at follow-up (P < 0.001 at lumbar spine, P < 0.05 at Ward's triangle). Concerning the association between BMD at follow-up and SHBG, in the premenopausal group, serum levels of SHBG were negatively correlated with BMD at the femoral neck (P < 0.05). In regard to partial regression coefficients for the change rates of BMD over 3 years and serum estrogens and SHBG concentrations, in perimenopausal women, UBE2 was correlated with the change rate of BMD at Ward's triangle (P < 0.05), and in postmenopausal group 1, serum levels of SHBG were significantly negatively related to change in BMD at the trochanter (P < 0.01). No other relationships with change in BMD were observed at any sites. These findings suggest that serum E2, UBE2, and SHBG levels differentially predict BMD levels in groups of differing menstrual status. It would, however, be difficult to predict bone loss in middle-aged and elderly Japanese women over a 3-year period using these indices alone. Received: November 29, 2001 / Accepted: February 28, 2002  相似文献   

17.
Measurements of bone biochemical markers are increasingly being used to evaluate the state of bone turnover in the management of bone metabolic diseases, especially osteoporosis. However, changes in the bone turnover rate vary with age. The aim of this study was to establish the laboratory reference range of serum bone-specific alkaline phosphatase (sBAP), serum type I collagen cross-linked C-terminal telopeptide (sCTx), and urine CTx (uCTx), based on values from 665 healthy Chinese women aged 20–80 years. We measured the levels of sBAP, sCTx, serum alkaline phosphatase (sALP), and uCTx and evaluated the age-related changes and their relationship with bone mineral density (BMD) in the anteroposterior (AP) lumbar spine, hip, and left forearm. We found significant correlations between biochemical markers and age, with coefficients of determination (R 2) of 0.358 for sBAP, 0.126 for sCTx, 0.125 for uCTx, and 0.336 for sALP. The net changes in different biochemical markers were inversely correlated with the rates of BMD loss in the AP lumbar spine. After correction for age, body weight, and height, the levels of the markers had significant negative correlations with the BMD of the AP lumbar spine, femoral neck, and ultradistal forearm. All four biochemical markers had the highest negative correlation with BMD of the AP lumbar spine (partial correlation coefficients of −0.366, −0.296, −0.290, and −0.258 for sBAP, sCTx, uCTx, and sALP, respectively). The mean and SD values of these markers in premenopausal and postmenopausal women with normal BMD values were used as the normal reference ranges. The reference ranges of sBAP, sCTx, and uCTx for pre- vs postmenopausal women were 17.3 ± 6.23 vs 18.9 ± 7.52 U/l, 3.18 ± 1.49 vs 3.23 ± 1.57 nmol/l, and 15.5 ± 11.4 vs 16.2 ± 12.4 nM bone collagen equivalents/mM urinary creatinine, respectively. Levels of the bone formation marker (sBAP) and bone resorption markers (sCTx, uCTx) increased rapidly in women with osteopenia or osteoporosis, indicating that they may be sensitive markers to determine the bone turnover rate in healthy Chinese women.  相似文献   

18.
目的探讨正常范围内促甲状腺激素(Thyroid Stimulating Hormone,TSH)水平对女性骨代谢指标的影响。方法选取896名甲状腺功能正常的女性,根据TSH水平进行三分位数法分组,未绝经组:T1组(0.27-2.00 mIU/L)、T2组(2.01-2.8mIU/L)及T3组(2.81-4.2 mIU/L);绝经组:T1组(0.27-2.01 mIU/L)、T2组(2.02-3.23 mIU/L)及T3组(3.24-4.2mIU/L)。比较各组间血钙、血磷、25(OH)vitD、腰围、BMI、BMD水平之间差异。spearman相关性分析TSH水平与骨量等级之间的相关性。以BMD作为因变量,对其分层后进行二元Logistic回归分析不同TSH水平对女性骨质疏松发生的影响。结果 (1)绝经期组T1组和T2组的左前臂BMD均明显低于T3组(P0.05),T1组和T2组右跟骨BMD均明显低于T3组(均P0.05);未绝经组3组间各指标无明显差异。(2)绝经组分层后的TSH水平与右跟骨、左前臂骨量等级呈负相关(r=-0.228,P0.05;r=-0.145,P0.05)。未绝经组分层后的TSH水平与右跟骨、左前臂骨量等级无相关性。(3)二元Logistic回归分析:以分组后的右跟骨BMD作为因变量,校正性别、年龄、BMI、腰围、血钙、血磷、25(OH)vitD后,绝经后女性T1组能够增加骨质疏松的风险(OR=2.278,95%CI 1.011~5.132,P0.05)。结论绝经后女性正常范围低水平TSH的骨密度更低,患骨质疏松的风险增高。  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号